| P2093 | author name string | C. E. Halstenson | |
| | P. A. Abraham | |
| | K. A. Redic-Kill | |
| | Redic-Kill KA | |
| | W. L. St Peter | |
| P2860 | cites work | Recombinant human erythropoietin for patients with AIDS treated with zidovudine | Q28330960 |
| | Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis | Q34072794 |
| | Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial | Q34182887 |
| | Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). | Q37713725 |
| | Treating renal anaemia with recombinant human erythropoietin: practical guidelines and a clinical algorithm | Q38066210 |
| | Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy | Q39465518 |
| | Low-dose recombinant human erythropoietin therapy in chronic hemodialysis patients | Q41189352 |
| | Characterization of the anaemia of chronic renal failure and the mode of its correction by a preparation of human erythropoietin (r-HuEPO). An investigation of the pharmacokinetics of intravenous erythropoietin and its effects on erythrokinetics | Q42012577 |
| | Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin | Q42156835 |
| | Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease | Q43529741 |
| | Recombinant erythropoietin and Medicare payment | Q44011292 |
| | Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients | Q45637493 |
| | Pharmacokinetics of intravenous recombinant human erythropoietin in patients with chronic renal failure | Q45728785 |
| | Experience of pain after subcutaneous administration of different preparations of recombinant human erythropoietin: a randomized, double-blind crossover study | Q51702376 |
| | Self-administered daily subcutaneous recombinant human erythropoietin: an open randomised dose-finding study in ESRD patients receiving peritoneal dialysis. | Q54082373 |
| | Hypertension following erythropoietin therapy in anemic hemodialysis patients. | Q54310942 |
| | The use of subcutaneous erythropoietin in CAPD patients. | Q64968841 |
| | A comparison of androgens for anemia in patients on hemodialysis | Q67281057 |
| | Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis | Q67781764 |
| | Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta | Q67781831 |
| | Pharmacokinetics and Dose Response after Intravenous and Subcutaneous Administration of Recombinant Erythropoietin in Patients on Regular Haemodialysis Treatment or Continuous Ambulatory Peritoneal Dialysis | Q67796033 |
| | Mortality and duration of hemodialysis treatment | Q67983224 |
| | Pharmacokinetics and pharmacodynamics of subcutaneous and intraperitoneal administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis | Q68707433 |
| | Statement on the clinical use of recombinant erythropoietin in anemia of end-stage renal disease. Ad Hoc Committee for the National Kidney Foundation | Q69533973 |
| | Experience with daily self-administered subcutaneous erythropoietin | Q69554449 |
| | Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials | Q69554458 |
| | Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial | Q69559204 |
| | Iron status in patients receiving erythropoietin for dialysis-associated anemia | Q69590794 |
| | Treatment of the anemia of progressive renal failure with recombinant human erythropoietin | Q69656934 |
| | Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis | Q69889300 |
| | Subcutaneous erythropoietin | Q69921739 |
| | Intraperitoneal erythropoietin | Q69928095 |
| | Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial | Q69934208 |
| | Erythropoietin | Q70139862 |
| | Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients | Q70168369 |
| | Subcutaneous erythropoietin: a comparison of daily and thrice weekly administration | Q70168373 |
| | Subcutaneous erythropoietin therapy: comparison of three different sites of injection | Q70168378 |
| | The response to recombinant human erythropoietin in patients with the anemia of end-stage renal disease is correlated with serum carnitine levels | Q70181350 |
| | Effect of recombinant human erythropoietin therapy on blood pressure in hemodialysis patients. Canadian Erythropoietin Study Group | Q70184963 |
| | Experience with low dose intravenous and subcutaneous administration of recombinant human erythropoietin | Q70253380 |
| | Effect of dialysis therapy on the hematopoietic system: the National Cooperative Dialysis Study | Q70264664 |
| | Two years experience of daily self-administered subcutaneous erythropoietin | Q70279702 |
| | Improving anemia by hemodialysis: effect of serum erythropoietin | Q71272791 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | erythropoietin | Q218706 |
| P304 | page(s) | 409-415 | |
| P577 | publication date | 1992-06-01 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | Controversies in determination of epoetin (recombinant human erythropoietin) dosages | |
| P478 | volume | 22 | |